SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

SCHEDULE 13G (Rule 13d-102)

INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b),(c) AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b)

(Amendment No.)¹

Aduro Biotech, Inc.				
(Name of Issuer)				
Common Stock, \$.0001 par value				
(Title of Class of Securities)				
007701.404				
00739L101				
(CUSIP Number)				
December 31, 2015				
(Date of Event Which Requires Filing of this Statement)				
Check the appropriate box to designate the rule pursuant to which this Schedule is filed:				
[] Rule 13d-1(b)				
[] Rule 13d-1(c)				
[X] Rule 13d-1(d)				
¹ The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page. The information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act.				

1.	NAME OF REPORTING PERSON						
	S.S. OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSON						
	Johnson & J						
	EIN: 22-10	24240					
2.	CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a)						
			(b) []				
3.	SEC USE ONLY						
	CIETAENICI III OD DI	A CE CE CE	C AND ATTON				
4.	CITIZENSHIP OR PLACE OF ORGANIZATION						
	New Jersey						
	NUMBER OF	5.	SOLE VOTING POWER -0-				
	SHARES	5.	SOLE VOING FOWER O				
	BENEFICIALLY	6.	SHARED VOTING POWER 3,906,207*				
	OWNED BY						
	EACH	7.	SOLE DISPOSITIVE POWER -0-				
	REPORTING						
	PERSON	8.	SHARED DISPOSITIVE POWER 3,906,207*				
	WITH						
9.	AGGREGATE AMO	AGGREGATE AMOUNT BENEFICIALLY OWNED					
	BY EACH REPORT	ING PERSC	DN 3,906,207*				
10.	CHECK BOX IF THE AGGREGATE AMOUNT						
	IN ROW (9) EXCLUD						
11.	PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9) 6.2%**						
12.	TYPE OF REPORTING PERSON CO						

^{*} As of December 31, 2015 ** Based on 63,224,033 shares of Common Stock outstanding as of November 20, 2015, as reported in the Issuer's Report on Form 10-Q for the period ended September 30, 2015 filed with the Securities and Exchange Commission on November 23, 2015.

1.	NAME OF REPORTING PERSON S.S. OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSON						
	Johnson & Johnson Inn	ovation-IIDC Inc					
	EIN: 22-2007137	ovation-33DC, file.					
2.	CHECK THE APPROPRIATE BC	X IF A MEMBER OF A	(a) []				
	GROUP		(b) []				
3.	SEC USE ONLY						
4.	CITIZENSHIP OR PLACE OF ORGANIZATION						
	New Jersey						
	NUMBER OF	5.	SOLE VOTING POWER -0-				
	SHARES						
	BENEFICIALLY OWNED BY EACH	6.	SHARED VOTING POWER 3,906,207*				
		7.	SOLE DISPOSITIVE POWER -0-				
	REPORTING	/.	SOLE DISPOSITIVE POWER -U-				
	PERSON	8.	SHARED DISPOSITIVE POWER 3,906,207*				
	WITH						
9.	AGGREGATE AMOUNT BEN	EFICIALLY OWNED					
	BY EACH REPORTING PERSO	ON 3,906,207*					
10.	CHECK BOX IF THE AGGREGA						
	AMOUNT IN ROW (9) EXCLUD	ES CERTAIN	[]				
	SHARES						
11.	PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9) 6.2%**						
12.	TYPE OF REPORTING PERSO	N CO					

^{*} As of December 31, 2015 ** Based on 63,224,033 shares of Common Stock outstanding as of November 20, 2015, as reported in the Issuer's Report on Form 10-Q for the period ended September 30, 2015 filed with the Securities and Exchange Commission on November 23, 2015.

SCHEDULE 13G

ITEM 1(a)	NAME OF ISSUER:
	Aduro Biotech, Inc.
ITEM 1(b)	ADDRESS OF ISSUER'S PRINCIPAL EXECUTIVE OFFICES:
	626 Bancroft Way, 3C Berkeley, CA 94710
ITEM 2(a)	NAME OF PERSON FILING:
	This statement is being filed by Johnson & Johnson, a New Jersey corporation ("J&J"), and Johnson & Johnson Innovation-JJDC, Inc., a New Jersey corporation ("JJDC"). JJDC is a wholly-owned subsidiary of J&J. The securities reported herein as being held by J&J and JJDC are directly beneficially owned by JJDC. J&J may be deemed to indirectly beneficially own the securities that are directly beneficially owned by JJDC.
ITEM 2(b)	ADDRESS OF PRINCIPAL BUSINESS OFFICE:
	One Johnson & Johnson Plaza New Brunswick, NJ 08933
ITEM 2(c)	CITIZENSHIP:
	J&J: New Jersey JJDC: New Jersey
ITEM 2(d)	TITLE OF CLASS OF SECURITIES:
	Common Stock, \$.0001 par value per share ("Common Stock")
ITEM 2(e)	CUSIP NUMBER:
	00739L101
ITEM 3	STATEMENTS FILED PURSUANT TO RULES 13D-1(B) OR 13D-2(B) OR (C):
	Not applicable.
ITEM 4	OWNERSHIP:
	The information set forth in Rows 5 through 9 and 11 of the cover pages of this Schedule 13G is incorporated herein by reference.
ITEM 5	OWNERSHIP OF FIVE PERCENT OR LESS OF A CLASS:
	Not applicable.
ITEM 6	OWNERSHIP OF MORE THAN FIVE PERCENT ON BEHALF OF ANOTHER PERSON:
	Not applicable.
ITEM 7	IDENTIFICATION AND CLASSIFICATION OF THE SUBSIDIARY WHICH ACQUIRED THE SECURITY BEING REPORTED ON BY THE PARENT COMPANY:
	Not applicable.

SIGNATURE

After reasonable inquiry and to the best of their knowledge and belief, the undersigned certify that the information set forth in this statement is true, complete and correct.

Dated: February 3, 2016

JOHNSON & JOHNSON

By: /s/ Thomas Spellman III

Name: Thomas Spellman III

Title: Secretary

JOHNSON & JOHNSON INNOVATION-

JJDC, INC.

By: /s/ Steven M. Rosenberg

Name: Steven M. Rosenberg

Title: Secretary